MC
NWBO

Moors & Cabot’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Moors & Cabot’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-10,000
Closed -$30K – 574
2015
Q4 		$30K Buy
+10,000
New +$48.1K 0.01% 492
2015
Q3 		– Sell
-11,100
Closed -$111K – 566
2015
Q2 		$111K Sell
11,100
-4,000
-26% -$35K 0.02% 488
2015
Q1 		$107K Hold
15,100
– – 0.02% 477
2014
Q4 		$77K Sell
15,100
-6,200
-29% -$31.7K 0.01% 487
2014
Q3 		$107K Sell
21,300
-2,000
-9% -$12.3K 0.02% 512
2014
Q2 		$158K Buy
+23,300
New +$148K 0.03% 497

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Moors & Cabot's NWBO Position: Q1 2016 in Review

Moors & Cabot sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q1 2016, closing a stake of 10,000 shares — an estimated $30K sold.

Moors & Cabot first reported a position in NWBO in Q2 2014 and held it in 6 quarters. The position peaked at $158K in Q2 2014. 74 funds tracked by Wall St. Rank hold NWBO as of Q1 2016.

  • Moors & Cabot reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q1 2016 after selling out during the quarter.
  • Moors & Cabot sold 10,000 Northwest Biotherapeutics, Inc. Common stock shares in Q1 2016, an estimated $30K.
  • Moors & Cabot first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2014 and held it in 6 quarters.
  • Moors & Cabot's Northwest Biotherapeutics, Inc. Common stock position peaked at $158K in Q2 2014.
  • 74 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q1 2016.

Based on Moors & Cabot's 13F filing for Q1 2016, filed 10 May 2016.